Joel T. Diamond

Partner

Principal outside counsel to life sciences companies on high-stakes strategic collaborations, IP licensing, and institutional partnerships

Joel helps life sciences companies structure the intellectual property transactions that shape their futures. His clients trust him with their most consequential partnering matters: complex collaborations, licenses, and strategic alliances that often represent bet-the-company decisions. He works with companies at every stage, from start-ups through mature businesses, and his practice spans the full lifecycle, from formation through late-stage financing and M&A.

Joel works across the entire life sciences ecosystem, encompassing biotechnology, pharmaceuticals, medical devices, diagnostics, and health care IT. He advises both the innovators developing next-generation technologies and the venture funds and institutional investors financing them. Clients rely on him for the full spectrum of strategic transactions, from core licensing and M&A to joint research collaborations, clinical trial networks, and global commercial supply partnerships.

Joel excels in structuring IP transactions with the world’s premier academic and research institutions, hospitals, and nonprofit organizations. Having negotiated directly with tech-transfer offices at Harvard, MIT, Stanford, Johns Hopkins, the Broad Institute, and the University of Pennsylvania, among others, he brings an insider’s perspective to the table. He understands the unique priorities and risk profiles of these institutions, enabling him to cut through administrative friction and drive complex partnerships forward efficiently.

Experience

Representative matters

Advised Go Therapeutics on a strategic collaboration, option, and license agreement with Astellas to develop novel antibodies for immuno-oncology, with a potential deal value of $783.5 million plus royalties.
Counseled QurAlis on a license and collaboration with Lilly for a potentially best-in-class therapy for neurodegenerative diseases, including ALS and frontotemporal dementia, with a potential deal value of $622 million plus royalties.
Represented Muna in a strategic alliance with GSK to accelerate development of novel treatments for Alzheimer’s disease, with a potential deal value of €733.5 million plus royalties.

Recognitions

  • Recognized by LMG Life Sciences as the U.S. Rising Star, Financial and Corporate, at the 2025 Life Sciences Americas Awards

Credentials

Education

  • Georgetown University Law Center, J.D.
  • Princeton University, B.S.E., Computer Science

Professional admissions & qualifications

  • Massachusetts

News

Media mentions

Insights